# COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19

> **NCT04403243** · PHASE2 · COMPLETED · sponsor: **Lomonosov Moscow State University Medical Research and Educational Center** · enrollment: 70 (actual)

## Conditions studied

- COVID 19

## Interventions

- **DRUG:** Colchicine
- **DRUG:** Ruxolitinib 5 MG
- **DRUG:** Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]
- **OTHER:** standard therapy

## Key facts

- **NCT ID:** NCT04403243
- **Lead sponsor:** Lomonosov Moscow State University Medical Research and Educational Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-08
- **Primary completion:** 2020-07-22
- **Final completion:** 2020-08-23
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2022-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04403243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04403243, "COLchicine Versus Ruxolitinib and Secukinumab in Open-label Prospective Randomized Trial in Patients With COVID-19". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04403243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*